| Identification | Back Directory | [Name]
PRN1008 | [CAS]
1575596-29-0 | [Synonyms]
PRN-1008-E
Rilzabrutinib
Rilzabrutinib (PRN-1008)
1-Piperidinepropanenitrile, 3-[4-amino-3-(2-fluoro-4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]-α-[2-methyl-2-[4-(3-oxetanyl)-1-piperazinyl]propylidene]-β-oxo-, (αE,3R)- | [Molecular Formula]
C36H40FN9O3 | [MDL Number]
MFCD31631583 | [MOL File]
1575596-29-0.mol | [Molecular Weight]
665.77 |
| Chemical Properties | Back Directory | [Boiling point ]
882.5±65.0 °C(Predicted) | [density ]
1.39±0.1 g/cm3(Predicted) | [storage temp. ]
Store at -20°C | [solubility ]
DMSO:120.0(Max Conc. mg/mL);180.24(Max Conc. mM) | [form ]
Solid | [pka]
6.24±0.70(Predicted) | [color ]
White to off-white | [InChIKey]
LCFFREMLXLZNHE-CNPRKNKUNA-N | [SMILES]
NC1N=CN=C2N([C@@H]3CCCN(C(=O)/C(/C#N)=C/C(N4CCN(C5COC5)CC4)(C)C)C3)N=C(C3C=CC(OC4C=CC=CC=4)=CC=3F)C=12 |&1:7,r| |
| Hazard Information | Back Directory | [Uses]
Rilzabrutinib (PRN1008) is a reversible covalent, selective and oral active inhibitor of Bruton’s Tyrosine Kinase (BTK), with an IC50 of 1.3 nM. | [in vivo]
In vivo Rilzabrutinib demonstrates enduring pharmacodynamic effects after the compound has cleared from circulation, consistent with extended target residence time. Rilzabrutinib also reverses and completely suppresses collagen-induced arthritis in rats in a dose dependent manner which allows correlation of target occupancy and disease modification[2]. | [IC 50]
BTK: 1.3 nM (IC50); BMX: 1.0 nM (IC50); ITK: 440 nM (IC50); TEC: 0.8 nM (IC50); RLK: 1.2 nM (IC50); BLK: 6.3 nM (IC50); EGFR: 520 nM (IC50); ERBB2: 3900 nM (IC50); ERBB4: 11.3 nM (IC50) | [References]
[1] Smith PF, et al. A phase I trial of PRN1008, a novel reversible covalent inhibitor of Bruton's tyrosine kinase, in healthy volunteers. Br J Clin Pharmacol. 2017 Nov;83(11):2367-2376. DOI:10.1111/bcp.13351
[2] Hill RJ, Bradshaw JM, Bisconte A, Tam D, Owens TD, Brameld KA, Smith PF, Funk JO, Goldstein DM, Nunn PA. Preclinical Characterization of PRN1008, a Novel Reversible Covalent Inhibitor of BTK that Shows Efficacy in a RAT Model of Collagen-Induced Arthritis. Annals of the Rheumatic Diseases 2015; 74(Suppl 2): 216. |
|
|